Related Experiment Video
Updated: Jun 21, 2026
Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice
Published on: August 25, 2023
Myocardial no-reflow in humans
Giampaolo Niccoli1, Francesco Burzotta, Leonarda Galiuto
1Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy. gniccoli73@hotmail.it
Insights
No-reflow, a complication of ST-segment elevation myocardial infarction treatment, occurs when epicardial arteries reopen but heart muscle does not. This review proposes personalized no-reflow management based on individual patient mechanisms.
Area of Science:
- Cardiology
- Interventional Cardiology
- Myocardial Infarction Research
Background:
- No-reflow phenomenon occurs in 5-50% of ST-segment elevation myocardial infarction patients post-primary percutaneous coronary intervention.
- This condition, characterized by epicardial reperfusion without myocardial reperfusion, is linked to poorer patient prognosis.
- No-reflow has a complex pathogenesis involving distal embolization, ischemia-reperfusion injury, and microvascular predisposition.
Purpose of the Study:
- To review the multifactorial pathogenesis of no-reflow.
- To discuss current and emerging therapeutic strategies for no-reflow prevention and treatment.
- To propose a novel, personalized management approach for no-reflow based on individual patient mechanisms.
Main Methods:
- Review of existing literature on no-reflow in ST-segment elevation myocardial infarction.
- Analysis of pathogenetic components including distal embolization, ischemia-reperfusion injury, and microvascular factors.
- Evaluation of clinical parameters and biomarkers for risk stratification and mechanism assessment.
Main Results:
- Thrombus aspiration before stenting improves myocardial perfusion and outcomes compared to standard procedures by reducing distal embolization.
- Despite mechanical interventions, no-reflow can still occur, indicating varied pathogenetic relevance among patients.
- Biomarkers and clinical parameters can predict no-reflow risk and aid in understanding its underlying mechanisms.
Conclusions:
- No-reflow is a significant complication with multifactorial causes, impacting patient outcomes after myocardial infarction treatment.
- Current therapies like thrombus aspiration address some mechanisms but do not universally prevent no-reflow.
- A personalized management strategy, tailored to the predominant mechanisms in individual patients, is proposed for improved no-reflow treatment.
Abstract:
In a variable proportion of patients presenting with ST-segment elevation myocardial infarction, ranging from 5% to 50%, primary percutaneous coronary intervention achieves epicardial coronary artery reperfusion but not myocardial reperfusion, a condition known as no-reflow. Of note, no-reflow is associated with a worse prognosis at follow-up. The phenomenon has a multifactorial pathogenesis including: distal embolization, ischemia-reperfusion injury, and individual predisposition of coronary microcirculation to injury. Moreover, it is spontaneously reversible in some patients, thus suggesting that it might be amenable to treatment also when we fail to prevent it. Several recent studies have shown that biomarkers and other easily available clinical parameters can predict the risk of no-reflow and can help in the assessment of the multiple mechanisms of the phenomenon. Several therapeutic strategies have been tested for the prevention and treatment of no-reflow. In particular, thrombus aspiration before stent implantation prevents distal embolization and has been recently shown to improve myocardial perfusion and clinical outcome as compared with the standard procedure. However, it is conceivable that the relevance of each pathogenetic component of no-reflow is different in different patients, thus explaining the occurrence of no-reflow despite the use of mechanical thrombus aspiration. Thus, in this review article, for the first time, we propose a personalized management of no-reflow on the basis of the assessment of the prevailing mechanisms of no-reflow operating in each patient.
